CRBN

Across TCGA pan-cancer cohorts, CRBN Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CRBN data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CRBN Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CRBN expression acts as an unfavorable survival marker.

LUAD, PRAD, and UCEC are the cancer types where CRBN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.381	0.814	<.001	54	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
HNSC	DFS	Median	All	0.136	0.625	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CRBN–LUAD (OS)

Open the LUAD breakdown →